Lupin Launches Raltegravir Tablets in US With 180-Day Generic Exclusivity

Lupin secures 180-day generic market exclusivity for Raltegravir 600 mg tablets in the U.S. market.
The reference product, Isentress HD, holds approximately USD 26 million in annual U.S. sales.

Reader Takeaway: Exclusive U.S. market access for 180 days provides a strong competitive advantage, though the total addressable market is niche.

What just happened

Lupin Limited has commercially launched Raltegravir Tablets, USP, 600 mg, in the United States following approval from the U.S. Food and Drug Administration. The tablets serve as a generic bioequivalent to Merck Sharp & Dohme’s Isentress HD Tablets, which are used to treat HIV-1 infections in adults and pediatric patients weighing 40 kg or more.

Why this matters

Lupin holds the status of being the exclusive first-to-file applicant. This designation entitles the company to 180 days of generic drug market exclusivity. This period allows Lupin to capture significant market share before other generic manufacturers enter the space, helping to bolster the revenue profile of its U.S. generics business unit.

Context metrics

According to IQVIA data for the period ending September 2026, the reference product, Isentress HD, reported annual U.S. sales of USD 26 million. While this is a modest market size relative to blockbuster drugs, the exclusivity provides a high-margin window to establish a footprint in the HIV treatment segment.

What to track next

Investors should monitor the company's ability to maximize market penetration during the 180-day exclusivity window and how effectively it manages supply chain logistics to meet demand for the antiretroviral treatment.